ABCB5 and recessive dystrophic epidermolysis bullosa: Under this premise, the identified therapeutic effects, which manifested themselves in decelerated RDEB cutaneous wound formation rates and accelerated and more stable healing of newly developed RDEB wounds, suggest a therapeutic advantage of repeated dosing of systemically administered ABCB5+ MSCs to patients with RDEB.